The PennZone

  • Home
  • Entertainment
  • Marketing
  • Non-profit
  • Technology
  • Construction
  • Education
  • Music
  • Health

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • Colonial Nissan Helps Multiple Generations of the Community Find Their Next Vehicle
  • ImagineX Acquires Payteros to Strengthen Digital Transformation Capabilities
  • From Pizza to Playlists: Marty The Pizza Guy Delivers Three Delicious New Songs
  • CAPO Supply Launches New Website Serving Western Pennsylvania and Eastern Ohio
  • Meals on Wheels of the Greater Lehigh Valley Receives $15,000 PPL Foundation Grant to Expand Access

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • Salestrics Introduces PraiseEngine: The AI-Native Review Engine Built to Fix Social Proof
  • BTAQ Unveils Easier Photo Upload Capabilities
  • K2 Integrity Names Michael Kallabat Global Head of Investigations and Disputes
  • WebDrafter Highlights How AI Search Is Reshaping Online Visibility
  • Socialhose Eyes Southeast Asia and Rejects the Copy-Paste Expansion Playbook

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!
  • Harrisburg's newest restaurant, Eleve, sells out entire inventory during Grand Opening
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • What's New in Hokkaido, Autumn 2026
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • Heidi G. Villari of The Villari Firm, PLLC Named to Super Lawyers for the Tenth Consecutive Year
  • Elevate Your Sneakers With Crep Protect Trek Laces
  • Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • SKRAP Finds Hope Through Heartache on Powerful New Single "Shellshock"
  • CodesClue: A Trusted AI-Based Software Development Company for Global Businesses
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Valgar LLC Launches The Briefing Room: Education Leaders
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
  • New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000

Popular on PennZone

  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Community Partnership Brings Live Theater to 150+ Young People
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Sara Abbas Receives "Eniochos" Charioteer Award at 2026 Who is Who International Awards

Similar on PennZone

  • The 'Tax Squeeze': Betsson's Record Quarter Previews the Economics of Finland's 2027 Casino Market
  • K2 Integrity Names Michael Kallabat Global Head of Investigations and Disputes
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Easwe D10, C20, and C30: Lightweight Folding Electric Wheelchairs Built for Easier Travel
  • Lineus Medical Signs Partnership Agreement with DIMA MedTech to Support Expansion into Italy
  • New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us